May 8 |
Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide
|
May 7 |
Summit spikes as Citi launches at Buy on lead asset
|
May 6 |
Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
|
May 2 |
Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript
|
May 2 |
Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
|
May 2 |
Q1 2024 Summit Therapeutics Inc Earnings Call
|
May 2 |
Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript
|
May 1 |
Summit Therapeutics Non-GAAP EPS of -$0.05 beats by $0.01
|
May 1 |
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
|
Apr 24 |
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
|